Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 28 min ago
Peer-reviewedCC BYAntioxidants (Basel, Switzerland)

Reduced Peritoneal NRF2 Immunoreactivity in Encapsulating Peritoneal Sclerosis and Its Implications for Redox Homeostasis.

  • Tina Oberacker1,2
  • Öztin Tüfek1,2
  • Tobias Leibold3
  • Adrian Salega3
  • Rebekka Schier1,2
  • Meng Dong1,2
  • Leonie Kraft4
  • Jörg Latus4
  • Severin Schricker4
  • Moritz Schanz4
4 affiliations
  1. 1Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Auerbachstr. 112, 70376 Stuttgart, Germany.
  2. 2University of Tübingen, Geschwister-Scholl-Platz, 72074 Tübingen, Germany.
  3. 3Department of General and Visceral Surgery, Robert Bosch Hospital Stuttgart, Auerbachstr. 110, 70376 Stuttgart, Germany.
  4. 4Department of Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart, Auerbachstr. 110, 70376 Stuttgart, Germany.
Read full textPDFDOICite

Abstract

Peritoneal dialysis (PD) is an effective modality of renal replacement therapy that provides patients with a high degree of autonomy. However, its long-term use is limited by the detrimental effects of PD fluids on the structure and function of the peritoneal membrane, ultimately leading to a loss of dialysis efficacy. Disruption of redox homeostasis plays a central role in these pathological changes, highlighting the importance of endogenous defense mechanisms in maintaining membrane integrity. Nuclear factor erythroid 2-related factor 2 (NRF2) is a key transcription factor regulating cellular antioxidant and cytoprotective responses. However, its immunoreactivity and localization in the peritoneal tissue of PD patients and patients with encapsulating peritoneal sclerosis (EPS) have not been well characterized. Therefore, we analyzed peritoneal biopsies from healthy controls, pre-dialysis patients, PD patients, and EPS patients. Immunohistochemical analysis demonstrated significantly reduced NRF2 immunoreactivity in patients with EPS compared with all other study groups. In contrast, nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) immunoreactivity was increased in PD and EPS patients. These results suggest that dysregulation of the NRF2-NFκB axis may be involved in peritoneal membrane injury, which warrants its further investigation as a potential target for preserving peritoneal membrane integrity during long-term PD.

Related

  1. Amyloid-Independent Elevation of Plasma phosphorylated tau-217 Tracks Neurodegenerative Risk in Tuberous Sclerosis Complex: Implications for mTOR-Targeted Intervention
    J. Baumel, M. Lutz, C. Ding +6
    medRxivPreprintAll rights reservedFull textNeurologymedRxiv
  2. Iron Supplementation and Copper Homeostasis: Evidence for Potential Copper Depletion, Biomarker Challenges, and Clinical Implications
    NutrientsPeer-reviewedCC BYFull textNutritionEurope PMC
  3. Hypertension in People with Multiple Sclerosis: Epidemiology, Mechanisms, Hypertensive Disorders of Pregnancy, and Clinical Implications.
    Ahmed Arafa, Amira S A Said, Ehab Elkady +3
    Diseases (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Hallmarks of aging in systemic sclerosis: implications for pathogenesis, multimorbidity, and therapeutic development.
    Maria Iacovantuono, Amela Hukara, Gesa Marie Sauer +5
    EULAR rheumatology openPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Fifteen-year real-world pharmacovigilance of multiple sclerosis disease-modifying therapies: adverse event profiles, drug-specific safety signals and clinical implications
    Sen Lin, Bei Zhang, Yingzhao Zhang +4
    Frontiers in NeurologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefPMC

Cite

BibTeXRIS
BibTeX
@article{oberacker2026reduced,
  title = {{Reduced Peritoneal NRF2 Immunoreactivity in Encapsulating Peritoneal Sclerosis and Its Implications for Redox Homeostasis.}},
  author = {Tina Oberacker and Öztin Tüfek and Tobias Leibold and Adrian Salega and Rebekka Schier and Meng Dong and Leonie Kraft and Jörg Latus and Severin Schricker and Moritz Schanz},
  journal = {Antioxidants (Basel, Switzerland)},
  year = {2026},
  month = sep,
  doi = {10.3390/antiox15101234},
  url = {https://europepmc.org/article/MED/42939808},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Reduced Peritoneal NRF2 Immunoreactivity in Encapsulating Peritoneal Sclerosis and Its Implications for Redox Homeostasis.
AU  - Tina Oberacker
AU  - Öztin Tüfek
AU  - Tobias Leibold
AU  - Adrian Salega
AU  - Rebekka Schier
AU  - Meng Dong
AU  - Leonie Kraft
AU  - Jörg Latus
AU  - Severin Schricker
AU  - Moritz Schanz
PY  - 2026
DA  - 2026/09/24
JO  - Antioxidants (Basel, Switzerland)
DO  - 10.3390/antiox15101234
UR  - https://europepmc.org/article/MED/42939808
AB  - Peritoneal dialysis (PD) is an effective modality of renal replacement therapy that provides patients with a high degree of autonomy. However, its long-term use is limited by the detrimental effects of PD fluids on the structure and function of the peritoneal membrane, ultimately leading to a loss of dialysis efficacy. Disruption of redox homeostasis plays a central role in these pathological changes, highlighting the importance of endogenous defense mechanisms in maintaining membrane integrity. Nuclear factor erythroid 2-related factor 2 (NRF2) is a key transcription factor regulating cellular antioxidant and cytoprotective responses. However, its immunoreactivity and localization in the peritoneal tissue of PD patients and patients with encapsulating peritoneal sclerosis (EPS) have not been well characterized. Therefore, we analyzed peritoneal biopsies from healthy controls, pre-dialysis patients, PD patients, and EPS patients. Immunohistochemical analysis demonstrated significantly reduced NRF2 immunoreactivity in patients with EPS compared with all other study groups. In contrast, nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) immunoreactivity was increased in PD and EPS patients. These results suggest that dysregulation of the NRF2-NFκB axis may be involved in peritoneal membrane injury, which warrants its further investigation as a potential target for preserving peritoneal membrane integrity during long-term PD.
SN  - 2076-3921
ER  -